Tetrahydrocannabivarin 是 cannabinoid type 1 receptor的中性拮抗剂，对 2 型糖尿病有潜在治疗价值。

Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.

At 3-1000 nanomol (nM), THCV did not prevent electrically induced contractions of mouse isolated vas deferens; though, the amount of THCV in this range formed dextral shifts in the log concentration-response curves of WIN and anandamide for electrically evoked contractions. These changes were not convoyed by a reduction in the maximal effect of any agonist. Nevertheless, at 3 millimolar (mM), THCV did lessen the contractile reaction of the vas deferens in a CB1 receptor antagonist (SR141716)-independent way. Moreover, THCV looks like SR141716 antagonist, which at high quantities also cooperates with non-CB1 targets.[1].

31262-37-0

C19H26O2

286.41

Tetrahydrocannavarin;CRM;THCV;delta9-Tetrahydrocannabivarin

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years